SUNNYVALE, Calif., Jan. 17, 2019 /PRNewswire/ -- According to
the American Cancer Society, prostate cancer is the most common
cancer in American men other than skin cancer. Accuray Incorporated
(NASDAQ: ARAY) and The Urology Group (TUG) are partnering to
recognize TUG's commitment to improving the lives of men with
prostate cancer. TUG physicians recently treated the center's
1,600th prostate cancer patient using the
CyberKnife® M6™ System, a groundbreaking radiotherapy
device that specializes in delivering stereotactic body radiation
therapy (SBRT) treatments with sub-millimeter precision. The
system's unique design and advanced treatment planning software
help enable physicians to avoid healthy tissue and minimize side
effects on urinary, bowel, and sexual function that can reduce a
man's quality of life.
One key step men can take to improve their health is to speak
with their physician about whether a prostate-specific antigen
(PSA) test, to screen for prostate cancer, is right for them. In
addition to PSA screening, there are other actions men can take to
maintain their overall good health and possibly reduce the risk of
prostate cancer. Though studies are mixed about the role of body
weight, physical activity, and diet on prostate cancer risk, the
American Cancer Society recommends that men:
- Eat no less than 2½ cups of a wide variety of fruits and
vegetables every day
- Be physically active
- Maintain a healthy weight
"For more than 20 years, The Urology Group has been dedicated to
delivering quality urologic care in our community," said
Gary M. Kirsh, M.D., President of
The Urology Group. "We encourage men to learn about medical
conditions that particularly impact them, such as prostate cancer.
It's critical that men understand their risk factors for developing
the disease and what a diagnosis means for them. The good news is
that innovations in care, such as the CyberKnife System, have
changed the way prostate cancer is managed, enabling physicians to
treat the disease with unparalleled preservation of healthy tissue
and provide substantial quality of life and lifestyle benefits to
patients."
The prostate gland can move unpredictably throughout the course
of treatment, making the ability to track, detect and correct for
motion critically important. In fact, the prostate has been
documented to move as much as 10 mm in as little as 30 seconds due
to normal patient bodily functions such as filling of the bladder,
gas in the bowel or even slight patient movement during the
procedure. The CyberKnife System's ability to automatically
stay on target despite patient and tumor motion is what
differentiates it from other types of radiation therapy delivery
systems. With true motion synchronization, it tracks the tumor
continually throughout the treatment session so that it can more
accurately deliver radiation to where the tumor is, not where it
used to be. CyberKnife SBRT is completed in 4-5 sessions instead of
the 30-40 sessions usually required with conventional radiation
therapy to safely spare normal tissues adjacent to the prostate,
and is noninvasive (no surgery involved).
"A cancer diagnosis can be devastating and the journey to
understand the disease and treatment options overwhelming," said
Lionel Hadjadjeba, M.D., Senior Vice President and Chief Customer
Experience Officer at Accuray. "We commend Dr. Kirsh and TUG team
on their dedication to providing their patients with the support
needed to identify the best solution for them and we are honored
that the clinical team has selected the CyberKnife technology to
treat so many of their prostate cancer patients. Published data
continue to reinforce the benefits of CyberKnife SBRT for the
treatment of low- and intermediate-risk prostate cancer. It is
proven to be safe and effective, while offering a convenient,
non-invasive approach that precisely targets the prostate cancer
with minimal disruption to patients' daily lives."
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About TUG
Headquartered in Cincinnati, Ohio,
The Urology Group is one of the largest single specialty groups of
urologists in the United States,
with 39 physicians on staff.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative treatment
solutions that set the standard of care with the aim of helping
patients live longer, better lives. The company's leading-edge
technologies deliver the full range of radiation therapy and
radiosurgery treatments. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, and patient experiences and outcomes. These
forward-looking statements involve risks and uncertainties. If any
of these risks or uncertainties materialize, or if any of the
company's assumptions prove incorrect, actual results could differ
materially from the results expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, the company's ability to achieve widespread
market acceptance of its products, the company's ability to develop
new products or enhance existing products to meet customers' needs,
the company's ability to maintain or increase its gross margins on
product sales and services, the company's ability to meet the
covenants under its credit facilities, the company's ability to
convert backlog to revenue and such other risks identified under
the heading "Risk Factors" in the company's annual report on Form
10-K, filed with the Securities and Exchange Commission (the "SEC")
on August 24, 2018, the company's
quarterly report on Form 10-Q, filed with the SEC on November 6, 2018, and as updated periodically
with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available
to Accuray at the time those statements are made and/or
management's good faith belief as of that time with respect to
future events. The company assumes no obligation to update
forward-looking statements to reflect actual performance or
results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent
required by applicable securities laws. Accordingly, investors
should not put undue reliance on any forward-looking
statements.
Media Contacts:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jayme Maniatis
MSLGROUP
+1 (781) 684-6610
accuray@mslgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/the-urology-group-surpasses-1-600-prostate-cancer-patients-treated-with-the-accuray-cyberknife-m6-system-300779533.html
SOURCE Accuray Incorporated